Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai and currently employs 285 full-time employees. The company went IPO on 2018-09-14. The firm is also engaged in the commercialization of HuaTangNing products. The Company’s main product pipeline dorzagliatin or HMS5552 is a glucokinase activator or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The firm mainly conducts its businesses in the domestic market.
Hua Medicine (Shanghai) Ltd.의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Hua Medicine (Shanghai) Ltd. 주요 수익원은 Dorzagliatin이며, 최신 수익 발표에서 수익은 277,423,619입니다. 지역별로는 China이 Hua Medicine (Shanghai) Ltd.의 주요 시장이며, 수익은 277,444,219입니다.
Hua Medicine (Shanghai) Ltd.은 수익성이 있나요?
no, 최신 재무제표에 따르면 Hua Medicine (Shanghai) Ltd.의 순손실은 $-250입니다.
Hua Medicine (Shanghai) Ltd.에 부채가 있나요?
예, Hua Medicine (Shanghai) Ltd.의 부채는 1,662입니다.
Hua Medicine (Shanghai) Ltd.의 발행 주식은 몇 주인가요?
Hua Medicine (Shanghai) Ltd.의 총 발행 주식은 983.66주입니다.